Clinical trials
Dermatitis clinical trials
Below are recruiting dermatitis clinical trials, each written for real people, not researchers. We’re tracking 227 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07754968Recruiting
Probiotic for formula-fed babies with colic
This study tests whether adding a probiotic called Bifidobacterium bifidum to formula can help reduce colic symptoms in babies who are not breastfed. It may also help if the baby has eczema (atopic dermatitis).
Roma, RMAges 1 week–5 months - NCT07235384RecruitingPhase 1
Zai Lab tests ZL-1503 for moderate to severe eczema
This study tests a new medication called ZL-1503 for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The trial will check if the drug is safe and how well it works.
Woolloongabba, QueenslandAges 18–65 - NCT06461897RecruitingPhase 3
Comparing upadacitinib to dupilumab for eczema in children
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
Little Rock, ArkansasAges 2–11 - NCT07290803Recruiting
Atopic dermatitis treatment registry for teens and adults
This study is a long-term registry for adolescents and adults with atopic dermatitis (eczema) who are starting or switching to a systemic medication (a drug that works throughout the body). It will track how these treatments work in real life and how patients feel over time.
Birmingham, AlabamaAges 12 years+ - NCT07223697RecruitingPhase 2
Long-term safety of Afimkibart for eczema patients
This study tests the long-term safety and effectiveness of a medicine called Afimkibart for people with atopic dermatitis (eczema). It is for people who already completed a previous study of this medicine and had at least a 50% improvement in their eczema.
Los Angeles, CaliforniaAges 18 years+ - NCT07643766RecruitingPhase 2
Testing ENV-294 for moderate-to-severe atopic dermatitis
This study tests whether a new medication called ENV-294 can help adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to other treatments. The trial will check if the drug reduces itching and skin inflammation safely.
Encinitas, CaliforniaAges 18 years+ - NCT06723080RecruitingPhase 3
Oral VC005 for moderate to severe eczema
This study tests an investigational oral tablet (VC005) for adults with moderate to severe atopic dermatitis (eczema). It is for people whose eczema has not been controlled well enough with topical treatments.
Nanjing, JiangsuAges 18–75 - NCT03057860Recruiting
Registry study for moderate to severe atopic dermatitis in Germany
This study is a national registry that collects information from people with moderate-to-severe atopic dermatitis (eczema). It helps doctors understand what treatments are used and how patients are doing over time.
Hanover, Lower SaxonyAges Any age - NCT07558668RecruitingPhase 1
Testing SYX-5219 for atopic dermatitis in healthy people and patients
This trial tests a new drug called SYX-5219 to see if it is safe and how the body handles it. Part 1 and 2 use healthy volunteers, while Part 3 tests it in people with moderate to severe atopic dermatitis (eczema). The goal is to understand if this drug might help treat eczema symptoms like itching and skin inflammation.
Arkansas City, ArkansasAges 18–65 - NCT07309055RecruitingPhase 3
Study of SHR-1819 injection for teens with severe eczema
This trial tests an injectable medicine called SHR-1819 for teenagers aged 12 to 17 with severe atopic dermatitis (eczema) that has not responded well to creams or other treatments. The goal is to see if it can improve skin symptoms and reduce itching.
Shenyang, LiaoningAges 12–17 - NCT06980961Recruiting
Laser treatment for stasis dermatitis (skin condition)
This study tests two types of laser devices (Omer Smart and Omer Premium) to see if they can help treat stasis dermatitis, a skin condition linked to poor blood flow in the legs. If you have already had treatment for varicose veins and your dermatitis is still bothering you, this trial may be an option.
Santo André, São PauloAges Any age - NCT06239311RecruitingPhase 3
Methotrexate vs placebo for adults with eczema
This trial tests if methotrexate, a medication that calms the immune system, can help adults with moderate-to-severe eczema that hasn't improved with creams or other treatments. You'll either receive methotrexate or a placebo to see which works better.
Prague, Praha 1Ages 18 years+ - NCT07690371RecruitingPhase 3
Study of rezpegaldesleukin for moderate to severe eczema
This study tests an experimental medicine (rezpegaldesleukin) for people with moderate to severe eczema. It aims to see if the drug can calm the immune system and improve skin symptoms when other treatments haven't worked.
Fountain Valley, CaliforniaAges 12 years+ - NCT06715982RecruitingPhase 2
JAK inhibitor for severe skin rash from immunotherapy
This study tests a JAK inhibitor pill for people with severe skin rashes caused by immunotherapy drugs like Keytruda or Opdivo. It aims to help control the rash and allow you to keep benefiting from your cancer treatment.
Quzhou, ZhejiangAges 18–80 - NCT06684522RecruitingEarly Phase 1
Upadacitinib for stubborn eyelid dermatitis
This study tests if the medication upadacitinib can help people whose eyelid rash has not improved with prescription creams. It's for adults who have had eyelid dermatitis for at least two months and have tried at least one prescribed cream that didn't work.
Chicago, IllinoisAges 18–70 - NCT07211542RecruitingPhase 2
Study of SHR-1905 for moderate-to-severe eczema
This trial tests a new drug called SHR-1905 for people with moderate-to-severe atopic dermatitis (a type of eczema). It aims to see if the drug is safe and helps improve symptoms.
Guangzhou, GuangdongAges 18–75 - NCT07022288Recruiting
Study of La Roche-Posay cream for mild facial eczema
This study tests whether a specific soothing moisturizer (La Roche-Posay B5 cream) helps people with mild, stable facial eczema. It is a simple, low-risk trial using a cream you can apply at home.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07711418RecruitingPhase 3
A study of rezpegaldesleukin for teenagers and adults with moderate-to-severe eczema
This trial tests an investigational drug called rezpegaldesleukin for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The goal is to see if it can safely reduce eczema symptoms.
The Bronx, New YorkAges 12 years+ - NCT07746427Recruiting
Mindfulness meditation for teens with eczema
This study tests whether a smartphone-based mindfulness meditation program can help teenagers with moderate to severe eczema (atopic dermatitis) that hasn't improved with standard creams. Participants will learn relaxation techniques to possibly reduce itching and skin inflammation.
New York, New YorkAges 12–17 - NCT06244212Recruiting
Atopic dermatitis treatment with steroid cream trial
This trial tests a common steroid cream (triamcinolone) for atopic dermatitis (a type of eczema). It aims to see how well it works in people who have active skin inflammation and can come back for a follow-up visit one week later.
Winston-Salem, North CarolinaAges 9 years+ - NCT04419584RecruitingPhase 2/Phase 3
Modified Qing-Ying decoction for children with eczema
This trial tests a traditional Chinese herbal formula (Modified Qing-Ying Decoction) for children ages 4 to 17 with moderate-to-severe eczema (atopic dermatitis). The study aims to see if this herbal treatment can improve skin dryness, redness, and itching, especially for those with dry, scaly patches.
Hong KongAges 4–17 - NCT07734441RecruitingEarly Phase 1
Itraconazole vs Ketoconazole for Scalp Seborrheic Dermatitis
This study compares two treatments—itraconazole pills and ketoconazole shampoo—for moderate to severe dandruff on the scalp. It aims to find which works better for teens aged 14–17.
Chak Four Hundred Fifty-four, Punjab ProvinceAges 18–65 - NCT07003425RecruitingPhase 2
Long-term safety and effectiveness of APG777 for eczema
This study looks at the long-term safety and how well APG777 works for people with eczema (atopic dermatitis). It is for people who have already completed treatment with APG777 in an earlier study and may benefit from continuing it.
Fountain Valley, CaliforniaAges 18 years+ - NCT07298395RecruitingPhase 2
Study of ENV-294 for moderate-to-severe eczema
This trial tests an experimental cream or pill called ENV-294 in adults whose eczema is moderate to severe and hasn't gotten better with standard creams. It aims to see if ENV-294 can help control symptoms like itching and skin redness.
Birmingham, AlabamaAges 18–75
Hear when a new Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for dermatitis?
- Yes. Clin2 currently lists 227 recruiting dermatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a dermatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a dermatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.